TOP TEN perturbations for 40018_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40018_at
Selected probe(set): 241425_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40018_at (241425_at) across 6674 perturbations tested by GENEVESTIGATOR:
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):4.2592087Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-3.9764051Number of Samples:3 / 5
| Experimental | ovarian tumor study 16 |
| Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):3.688613Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
stem cell differentiation study 41 (T3pi) / undifferentiated hES-T3 cell sample
Relative Expression (log2-ratio):-3.4464092Number of Samples:2 / 3
| Experimental | stem cell differentiation study 41 (T3pi) |
| Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype. | |
| Control | undifferentiated hES-T3 cell sample |
| Undifferentiated human embryonic stem cells T3. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):3.3600569Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):3.3221626Number of Samples:4 / 2
| Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
CAR T cell study 4 (PSCA-28t28Z; pre-infusion) / CAR T cell study 4 (GFP; pre-infusion)
Relative Expression (log2-ratio):3.18264Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). | |
| Control | CAR T cell study 4 (GFP; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)
Relative Expression (log2-ratio):-2.9658852Number of Samples:7 / 8
| Experimental | precursor-B-ALL study 7 (PDX; long-term; >10wk) |
| Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis). | |
| Control | precursor-B-ALL study 7 (late relapse; >24m) |
| Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457. |
CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion) / CAR T cell study 4 (GFP; pre-infusion)
Relative Expression (log2-ratio):2.6557207Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). | |
| Control | CAR T cell study 4 (GFP; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
hypoxia study 5 / untreated pancreas carcinoma cell line (FG) sample
Relative Expression (log2-ratio):2.5604553Number of Samples:3 / 3
| Experimental | hypoxia study 5 |
| Human metastatic pancreas carcinoma cell line FG with low metastatic potential in xenografts grown in culture under reduced oxygen. | |
| Control | untreated pancreas carcinoma cell line (FG) sample |
| Human metastatic pancreas carcinoma cell line FG with low metastatic potential in xenografts grown in culture under normoxia. |